Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:ONS

Oncobiologics (ONS) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)
Free ONS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$7.18
▼
$7.92
50-Day Range
$0.72
▼
$7.40
52-Week Range
$0.57
▼
$1.53
Volume
187,970 shs
Average Volume
69,024 shs
Market Capitalization
$561.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
ONS stock logo

About Oncobiologics Stock (NASDAQ:ONS)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

ONS Stock News Headlines

August 2, 2023 | mirror.co.uk
BBC slammed for 'biased' Wimbledon coverage of Marketa Vondrousova vs Ons Jabeur final
July 30, 2023 | mirror.co.uk
Ons Jabeur ‘kicked off’ Wimbledon centre court moments before women’s final
April 27, 2023 | nytimes.com
Are Away Carry-Ons Worth the Hype?
October 5, 2022 | dailymail.co.uk
ONS - the Office of National Statistics
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ONS
Previous Symbol
NYSE:ONS
CUSIP
N/A
CIK
1649989
Web
www.oncobiologics.com
Phone
(609) 619-3990
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,840,000.00
Net Margins
-464.47%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-93.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.41
Quick Ratio
0.41

Sales & Book Value

Annual Sales
$3.81 million
Price / Sales
147.43
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-5.72

Miscellaneous

Outstanding Shares
72,200,000
Free Float
N/A
Market Cap
$561.72 million
Optionable
Not Optionable
Beta
-0.27

Key Executives

  • Lawrence A. Kenyon
    President, CEO, CFO, Secretary & Treasurer
  • Terry Dagnon
    Chief Operating Officer
  • Jennifer M. Kissner
    Senior Vice President-Clinical Development
  • Jeff Evanson
    Chief Commercial Officer

Key Competitors

View All Competitors

ONS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Oncobiologics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncobiologics investors own include CRISPR Therapeutics (CRSP), Network-1 Technologies (NTIP), Allena Pharmaceuticals (ALNA), Intra-Cellular Therapies (ITCI), Cidara Therapeutics (CDTX), Neuralstem (CUR), Exelixis (EXEL), Fate Therapeutics (FATE), Ampliphi Biosciences (APHB) and Ardelyx (ARDX).

When did Oncobiologics IPO?

Oncobiologics (ONS) raised $35 million in an initial public offering on Friday, May 13th 2016. The company issued 5,800,000 shares at $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

This page (NASDAQ:ONS) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Elon to Transform U.S. Economy?
Porter & Company
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts